Zydus Cadila gets USFDA nod for overactive bladder drug

Zydus Cadila said it received the final approval to launch overactive bladder drug Fesoterodine Fumarate in the US.

The sales of Fesoterodine Fumarate Extended-Release Tablets are estimated at $195.5 million.

It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Fesoterodine is used to treat an overactive bladder with Symptoms of urinary frequency, urgency, and incontinence.

It said the group now has more than 160 approvals and has so far filed over 300 ANDAS since the commencement of the filing process in FY 2003-04.

Cadila was founded in 1952 by Ramanbhai Patel, formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. It evolved over the next four decades into an established pharmaceutical company and is today one of the world’s largest producers of generic drugs.